Golimumab for moderate to severe ulcerative colitis

Strik, Anne S.; Berends, Sophie E.; Mathôt, Ron A. A.; D’Haens, Geert R.; Löwenberg, Mark

doi:10.1080/17474124.2017.1303376

Cited by 7 publications

(9 citation statements)

References 34 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The commercial product, which is produced in a recombinant cell line culture, binds to the soluble and transmembrane forms of TNF-α and acts as an inhibitor. 38 This agent has been approved for use in moderately to severely active RA, psoriatic arthritis, ankylosing spondylitis, and moderately to severely active UC. 39 The European Medicines Agency has further approved it for JIA in combination with methotrexate for children >40 kg body weight.…”

Section: Discussionmentioning

confidence: 99%

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Rawla

Sunkara

Raj

2018

JIR

112

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and so the number of agents used in their treatment. Biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available, which provide therapeutic benefits to the IBD patients. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) are approved for use in IBD. Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This review summarizes the clinical pharmacology, studies leading to their approval, overall indications and their use in IBD, usage in pregnancy and lactation, and the adverse effects of these agents. This review also summarizes the recent advances and future perspectives specific to biologics and biosimilars in IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Rawla

Sunkara

Raj

2018

JIR

112

View full text Add to dashboard Cite

show abstract

“…In Crohn's disease, concomitant use of immunomodulators was associated with a lower adverse drug reaction‐mediated discontinuation rate, specifically infusions reactions, as reported elsewhere 31,46,47 . In contrast to some previous data, 19 treatment outcomes did not differ between patients who switched because of intolerance to the first anti‐TNF and those who switched because of poor clinical effectiveness.…”

Section: Discussionmentioning

confidence: 47%

Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register

Visuri¹,

Eriksson²,

Olén³

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Whether long‐term effectiveness differs between anti‐tumour necrosis factor (anti‐TNF) agents is unknown. Aims To examine drug survival of first‐line anti‐TNF agents and identify predictors of discontinuation. To reduce channelling bias, we also compared drug survival of the second anti‐TNF. Methods Biologic‐naïve patients (N = 955) recorded in the Swedish IBD Quality Register (SWIBREG) were examined. We used propensity score matching, comparing drug survival over up to three years of follow‐up. Cox regression estimated adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). Results In Crohn's disease, discontinuation because of lack/loss of response was 32% [95%CI = 26%‐38%] for infliximab versus 16% [95%CI = 11%‐21%] for adalimumab. Infliximab [vs adalimumab; aHR = 1.96; 95%CI = 1.20‐3.21] and colonic disease (L2) [vs no L2; aHR = 2.17; 95% CI = 1.26‐3.75] were associated with higher discontinuation rates, whereas normalised CRP at three months [aHR = 0.40; 95% CI = 0.19‒0.81] with a lower rate. Consistently, patients who switched from adalimumab to infliximab (vs infliximab to adalimumab) had earlier discontinuation (P = 0.04). Concomitant use of immunomodulators was associated with a lower adverse drug reaction‐mediated discontinuation rate [aHR = 0.46; 95% CI = 0.28‐0.77], in part explained by fewer infusion reactions [aHR = 0.27; 95% CI = 0.08‐0.89]. In ulcerative colitis, the probability of discontinuation because of lack/loss of response was 40% [95% CI = 33%‐47%] for infliximab versus 37% [95% CI = 21%‐53%] for adalimumab. Disease duration ≥10 years [aHR = 0.25; 95% CI = 0.10‐0.58] and normalised CRP after three months [aHR = 0.39; 95% CI = 0.18‒0.84] were associated with lower discontinuation rates. Conclusions Clinical characterisation of patients may aid decision‐making on anti‐TNF treatment. The consistently shorter drug survival for infliximab (vs adalimumab) in Crohn's disease, suggests a potential difference between the two drugs.

show abstract

“…Pre liečbu UC, ale nie CD, schválila roku 2013 FDA aj EMA ďalšiu anti-TNF mAb -golimumab. Je plne humánna, v porovnaní s adalimumabom neutralizuje TNF účinnejšie, avšak jej miesto v anti-TNF liečbe nie je ešte pevne stanovené [54].…”

Section: Monoklonové Protilátky a Malé Molekuly V Liečbe Ulceróznej Kolitídyunclassified

“…V nemalej miere rozhodnutie lekára ovplyvňujú aj samotní pacienti, napr. môžu preferovať spôsob aplikácie biologika (intravenózny vs subkutánny) alebo frekvenciu podávania (každých 8 týždňov pri IFX, alebo každý týždeň či každý 2. týždeň pri ADA, alebo každý 4. týždeň pri GLM; udržiavacia liečba) [54].…”

Section: Tab Prehľad Monoklonových Látok a Malých Molekúl V Liečbe Crohnovej Choroby A Ulceróznej Kolitídyunclassified

See 1 more Smart Citation

Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases

Buc¹

2018

Vnitr Lek

View full text Add to dashboard Cite

Idiopatické zápalové choroby čreva (inflammatory bowel diseases -IBD), ku ktorým zaraďujeme Crohnovu chorobu (Crohn's disease -CD) a ulceróznu kolitídu (ulcerative colitis -UC), charakterizuje chronický zápal čreva, ktorý spôsobuje progresívne poškodenie čreva, čo má značný nepriaznivý dopad na zdravie pacienta. Etiopatogenézu IBD stále ešte úplne nepoznáme, i keď už vieme, že vývoj IBD podmieňuje interakcia environmentálnych faktorov, genetickej predispozície, zmien intestinálneho mikrobiómu a poruchy imunitnej homeostázy [1,2]. Imunopatogenéza Crohnovej choroby a ulceróznej kolitídy Crohnova chorobaPatogenéza CD je komplexná, s účasťou početných buniek a molekúl. Súčasné poznatky naznačujú, že Crohnova choroba sa vyvíja viacstupňovo. Proces spočiatku charakteri-

show abstract

Golimumab for moderate to severe ulcerative colitis

Cited by 7 publications

References 34 publications

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register

Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases

Contact Info

Product

Resources

About